Pfizer, Inc. (PFE) Analyst Ratings & Price Targets

Pfizer, Inc.

PFE · NYSE

Analyst Consensus

Hold

20 analysts

$27

Current

—

Low

$28

Average

—

High

Average target implies +4.52% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Hold across 20 analysts, with a mean price target of $28. No low or high target is provided, so the target spread and its clustering cannot be measured. The evidence also does not identify the most bullish or least bullish analyst, and it contains no attributable analyst rating or price-target revisions during the week. The substantive investment debate visible in the supplied research is instead operational: Pfizer beat second-quarter earnings and revenue estimates, raised the low end of its 2026 sales outlook and maintained its earnings view, but reduced expected COVID-product revenue and posted a quarterly loss because of one-time charges. Those mixed signals explain why the available consensus is not more constructive, although the evidence does not establish analyst-specific disagreement.

Rating Actions

No individual rating actions have been captured for PFEyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BARCLAYS CAPITA

BMO CAPITAL MKT

CANTOR FITZGERA

CITIGROUP

CO FORECST

DAIWA AMERICA

EDWARD JONES

GOLDMAN SACHS

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

ROTHSCHILD REDB

TD COWEN

TRUIST SECURITI

UBS

WELLS FARGO SEC

ZACKS RESEARCH

Symbol: PFE
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: NYSE

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.

Key Issues

Bullish view

Pfizer exceeded second-quarter revenue estimates and raised the low end of its 2026 sales outlook, suggesting broader products can offset some COVID normalization.

Bearish view

Management lowered its COVID-product revenue expectations, and the supplied evidence does not identify which other products or businesses will provide enough growth to close that gap.

Analyst Consensus

See all

Hold

20 analysts

$27

Current

—

Low

$28

Average

—

High

Average target implies +4.52% versus the current price.

Earnings History

BeatMissNo estimate

Pfizer, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers